GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects
Phase 3
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 256
- Registration Number
- NCT00246701
Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension
Phase 4
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2009-12-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 167
- Registration Number
- NCT00246636
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase 2
Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: GW786034Drug: Placebo
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 225
- Registration Number
- NCT00244764
- Locations
- 🇨🇳
GSK Investigational Site, Taipei, Taiwan
This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic
- Conditions
- Hypereosinophilic Syndrome
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00244686
Odiparcil For The Prevention Of Venous Thromboembolism
Phase 2
Completed
- Conditions
- Deep Vein ThrombosisFibrillation, AtrialVenous ThromboembolismPulmonary Embolism
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 961
- Registration Number
- NCT00244725
- Locations
- 🇬🇧
GSK Investigational Site, Wigan, United Kingdom
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
Phase 2
Completed
- Conditions
- Cirrhosis, Liver
- Interventions
- Drug: GI262570 1.0 mgDrug: GI262570 0.5 mgDrug: Placebo
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 265
- Registration Number
- NCT00244751
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan
Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV
Phase 4
Completed
- Conditions
- HIV Infection
- Interventions
- Drug: abacavir/lamivudineDrug: emtricitabine/tenofovir
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2010-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 688
- Registration Number
- NCT00244712
- Locations
- 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico
Use Of GW274150 In The Prophylactic Treatment Of Migraine
Phase 2
Completed
- Conditions
- Migraine Disorders
- Interventions
- Drug: GW274150Other: Placebo
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 430
- Registration Number
- NCT00242866
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
A Study To Investigate Markers Of Inflammation In Rheumatoid Arthritis
Completed
- Conditions
- Rheumatoid ArthritisOsteoarthritis
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00242853
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants
Phase 3
Completed
- Conditions
- Infections, Rotavirus
- Interventions
- Biological: Rotarix™Biological: Placebo
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2016-12-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2089
- Registration Number
- NCT00241644
- Locations
- 🇿🇦
GSK Investigational Site, Tembisa, South Africa
© Copyright 2025. All Rights Reserved by MedPath